GSK3A and acute myeloid leukemia: Consistent with GSK3α being overexpressed across all major AML karyotypes (Figure S1a), tivantinib efficacy did not show any obvious relationship with mutational status or karyotypes (Fig. 5a; Table S2) although the number of patient samples was low.